A predictive model for selecting patients with HCV genotype 3 chronic infection with a high probability of sustained virological response to peginterferon alfa-2a/ribavirin

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Asselah, Tarik ^a   Thompson, Alex J ^b   Flisiak, Robert ^c   Romero Gomez, Manuel ^d   Messinger, Diethelm ^e   Bakalos, Georgios ^f   Shiffman, Mitchell L ^g  

^a CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^e PROMETRIS GmbH   (Germany)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g Bon Secours Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CAUCASIAN; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT SELECTION; PROBABILITY; RETROSPECTIVE STUDY; SCORING SYSTEM; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT; TREATMENT RESPONSE; ADOLESCENT; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; THEORETICAL MODEL; VALIDATION STUDY; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MODELS, THEORETICAL; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; VIRAL LOAD; YOUNG ADULT;

EID: 84962195826     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150569     Document Type: Article

References (33)

1. Mohd Hanafia K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seropre valence. Hepatology. 2013; 57: 1333-1342. doi: 10.1002/hep.26141 PMID: 23172780.
2. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Available at http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/Accessed 15 May 2015.
3. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl): S45-S57. doi: 10.1016/j.jhep.2014.07.027 PMID: 25086286.
4. Ampuero J, Romero-Gomez M, Reddy KR. HCV genotype 3-the new treatment challenge. Aliment Pharmacol Ther. 2014; 39: 686-698. PMID: 24612116.
5. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Müllhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009; 51: 655-666. doi: 10.1016/j. jhep.2009.05.016 PMID: 19665246.
6. Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, et al. HCV genotype 3 is associated with a higher hepato cellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat. 2011; 18: e516-e522. doi: 10.1111/j.1365-2893.2011.01441.x PMID: 21914071.
7. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: The best interferonfree combinations. Liver Int. 2014; 34(Suppl 1): 69-78. doi: 10.1111/liv.12423 PMID: 24373081.
8. EASL. Recommendations on treatment of hepatitis C 2015.J Hepatol. 2015; 63: 199-236. doi: 10. 1016/j.jhep.2015.03.025 PMID: 25911336.
9. Foster GR, Pianko S, Cooper C, Brown A, Forton D, Nahass RG, et al. Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The BOSON study (abstract L05). J Hepatol. 2015; 62: S259-S260.
10. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014; 370: 1993-2001. doi: 10.1056/NEJMoa1316145 PMID: 24795201.
11. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370: 211-221. doi: 10.1056/NEJMoa1306218 PMID: 24428467.
12. Ward JW, Mermin JH. Simple, effective, but out of reach? Public health implications of HCV drugs. N Engl J Med 2015; 373: 2678-2680. doi: 10.1056/NEJMe1513245 PMID: 26575359.
13. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932-954. doi: 10.1002/hep.27950 PMID: 26111063.
14. Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating hepatitis C in lower-income countries. N Engl J Med. 2014; 370: 1869-1871. doi: 10.1056/NEJMp1400160 PMID: 24720680.
15. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007; 357:124-134. PMID: 17625124.
16. Diago M, Shiffman ML, Bronowicki JP, Zeuzem S, Rodriguez-Torres M, Pappas S, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology. 2010; 51: 1897-1903. doi: 10.1002/hep.23531 PMID: 20196118.
17. Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology. 2012; 56:2039-2050. doi: 10.1002/hep.25892 PMID: 22706730.
18. Foster GR, Coppola C, Derbala P, Ferenci P, Orlandini A, Tallarico S, et al. Baseline predictors for safety-related dose reductions or treatment discontinuations among peginterferon alfa-2a (40KD)/ribavirin- Treated patients and their impact on early treatment responses: GUARD-C interim analysis (abstract). J Hepatol. 2012; 56(Suppl): S437-S438.
19. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med. 2004; 23: 1631-1660. PMID: 15122742.
20. Hadziyannis SJ, Sette H Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140: 346-355. PMID: 14996676.
21. Ferenci P, Aires R, Ancuta I, Arohnson A, Cheinquer H, Delic D, et al. A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin. Liver Int. 2014; 34: 1550-1559. doi: 10.1111/liv.12439 PMID: 24329937.
22. Heidrich B, Wiegand SB, Buggisch P, Hinrichsen H, Link R, Möller B, et al. Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. PLoS One. 2014; 9: e108751. doi: 10.1371/journal.pone.0108751 PMID: 25302676.
23. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology. 2004; 40: 1260-1265. PMID: 15558712.
24. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005; 352: 2609-2617. PMID: 15972867.
25. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005; 129: 522-527. PMID: 16083709.
26. Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007; 56: 553- 559. PMID: 16956917.
27. Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008; 47: 35-42. PMID: 17975791.
28. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Randomized comparison of 12 or 24 weeks of peginterfer on alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 2008; 47: 1837-1845. doi: 10.1002/hep.22253 PMID: 18454508.
29. Zeuzem S, Rizzetto M, Ferenci P, Shiffman ML. Management of hepatitis C virus genotype 2 or 3 infection: Treatment optimization on the basis of virological response. Antivir Ther. 2009; 14: 143-154. PMID: 19430089.
30. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461: 399-401. doi: 10.1038/nature08309 PMID: 19684573.
31. Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjoro K, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology. 2011; 53: 746-754. doi: 10.1002/hep.24154 PMID: 21374656.
32. Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011; 9: 344-350. doi: 10.1016/j.cgh.2010.07.019 PMID: 20728570.
33. Firdaus R, Biswas A, Saha K, Mukherjee A, Chaudhuri S, Chandra A, et al. Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients. PLoS One. 2014; 9: e99126. doi: 10.1371/journal.pone.0099126 PMID: 24914551.